RSV Protection for Infants

Two ways to protect babies from RSV — an antibody given to the infant, or a vaccine given in pregnancy.

Infant / risk-based Publicly funded
Disease Protected Against
RSV (respiratory syncytial virus) — a common cause of coughs and colds that can be serious in babies, sometimes causing bronchiolitis or pneumonia.
Two approaches
Beyfortus® (nirsevimab): an antibody given directly to the infant. Abrysvo®: a vaccine given to the pregnant parent to pass protection to the baby.
Ontario Timing
Seasonal — around the RSV season (typically fall through early spring). Beyfortus for eligible infants; Abrysvo in pregnancy at 32–36 weeks.
Publicly Funded Status
Yes — both are provided free for eligible families through Ontario's RSV prevention program.
Bottom line: RSV protection for babies works differently from most vaccines. There are two options: Beyfortus, a ready-made antibody given to the infant (the NACI-preferred option), or Abrysvo, a vaccine given during pregnancy so the parent passes antibodies to the baby. Usually only one is needed — not both. It's not a school vaccine; it's seasonal infant protection, free for eligible families in Ontario.
This guidance changes by season. RSV protection products, eligibility (birth-date ranges, age cut-offs, and high-risk criteria), and recommendations are set each season and can change year to year. Check current Ontario and Canadian guidance, or speak with a healthcare provider or local public health unit, before making decisions.

What it protects against

RSV (respiratory syncytial virus) is a very common respiratory virus. In older children and adults it's usually like a cold, but in babies — especially young infants — it can be more serious.

Aspect What parents might notice How it spreads Why it can be serious How protection helps
RSV illness in babies Runny nose, cough, reduced feeding, and sometimes fast or laboured breathing, wheezing, or pauses in breathing in very young infants. Through respiratory droplets from coughing and sneezing, and by contact with contaminated hands and surfaces. It spreads very easily. In infants, RSV can cause bronchiolitis (inflammation of the small airways) or pneumonia. It's one of the most common reasons babies are hospitalized, especially in the first months of life. Both the infant antibody and the maternal vaccine substantially reduce the chance of severe RSV illness and hospitalization in babies.
Almost all children catch RSV at least once by age two, and most recover at home. The goal of RSV protection isn't to prevent every cold — it's to reduce the severe illness and hospitalizations that RSV can cause in the youngest, most vulnerable babies, particularly during their first RSV season.

Two ways to protect a baby from RSV

RSV protection for infants is unusual because there are two different approaches, and they work in different ways. Usually a baby only needs one of them, not both.

1. Beyfortus® (nirsevimab) — given to the baby. This is a monoclonal antibody, not a vaccine. Rather than prompting the baby's own immune system to make antibodies (which takes time), it provides ready-made antibodies directly, giving immediate protection. It's a single injection, and protection lasts at least about 6 months — covering the baby through their first, most vulnerable RSV season. Ontario's program (and NACI) prefer Beyfortus for infant protection, based on its effectiveness and duration.

2. Abrysvo® — given during pregnancy. This is a vaccine given to the pregnant parent, usually between 32 and 36 weeks of pregnancy, when the baby is due during RSV season. The parent's immune system makes antibodies that cross the placenta to the baby, so the newborn is born with protection. This protection is passed on and fades over the baby's first several months.

Which one, and why usually just one? If the maternal vaccine (Abrysvo) was given during pregnancy, the baby usually does not also need Beyfortus — they're already protected. Beyfortus is typically used when the parent didn't receive the vaccine, when protection might be insufficient (for example, the baby was born within about two weeks of the vaccine), or for premature and high-risk infants. A healthcare provider helps decide the best approach for your situation.

Timing: Both are timed around the RSV season (typically November through March). Beyfortus is given to eligible infants entering or born during the season; high-risk children may be eligible up to 24 months. Abrysvo is given in the third trimester for babies due during the season.

Can these be given with other vaccines? Yes. Abrysvo can be given alongside other pregnancy vaccines (like Tdap, flu, and COVID-19), and Beyfortus can be given around the same time as a baby's routine vaccines. Different injection sites are used.

Eligibility changes by season. RSV programs are relatively new and the specific eligibility (birth dates, age cut-offs, high-risk criteria) is set each season. For the current season's exact eligibility and dates, check Ontario's RSV prevention program page or ask your healthcare provider or public health unit.

School and reporting status

RSV protection is not part of Ontario's school requirements. It's infant and high-risk-child protection given in the first months and years of life — long before school — so it's not one of the diseases under the Immunization of School Pupils Act (ISPA).

Instead, RSV protection is offered through Ontario's Infant and High-Risk Children RSV Prevention Program, which provides Beyfortus and Abrysvo free to eligible families during the RSV season. It's about protecting babies when they're most vulnerable, not about school entry.

Reporting: Whether your baby received Beyfortus, or you received Abrysvo in pregnancy, it's worth keeping a note on your child's health record so future providers know what protection was given. The provider who administers it can record it.

High-risk children: Some children with certain medical conditions (such as those born prematurely, or with heart or lung conditions) may be eligible for RSV protection up to 24 months of age, and may have different recommendations. A healthcare provider can advise based on your child's situation.

What's in these products

The two RSV products work differently, so their ingredients differ. Beyfortus® (nirsevimab) is a monoclonal antibody given to the infant; Abrysvo® is a protein-based vaccine given in pregnancy. The information below reflects the general categories from their Health Canada product monographs. Neither contains a live virus, and neither can cause RSV.

Ingredient / Component Product Category Plain-English explanation
Nirsevimab (a monoclonal antibody) Beyfortus Active ingredient A lab-made antibody — the same kind of protective protein the body itself makes — designed to recognize and block RSV. It provides protection directly, without needing the baby's immune system to build its own response.
RSV "F" proteins (stabilized, from two RSV subgroups) Abrysvo Active ingredient Purified copies of a protein from the surface of RSV. They contain no live virus and can't cause RSV — they teach the pregnant parent's immune system to make protective antibodies that pass to the baby.
Sugars (e.g. sucrose) and amino acids (e.g. histidine, arginine) Both Stabilizers / buffers Help keep the product stable and at a body-friendly acidity. Amino acids are the building blocks of proteins, found throughout the body.
Polysorbate (80 or 20) Both Stabilizer A common ingredient in many foods and medicines that helps keep the product stable.
Salts (e.g. sodium chloride) Both Tonicity agent Ordinary salts so the injection is gentle on the tissues.
Water for injection Both Base Sterile water making up most of the injection.
Antibody vs. vaccine — the key difference: A vaccine (like Abrysvo) trains the immune system to make its own antibodies, which takes a couple of weeks. A monoclonal antibody (like Beyfortus) is the antibody — it works right away but fades over months as the body clears it. Both are well studied; neither contains live virus. For exact contents, ask your provider or check the product monograph.

Side effects and safety

Expected / common side effects

  • Beyfortus (infant): redness, swelling, or soreness where the injection was given; occasionally a rash or mild fever
  • Abrysvo (in pregnancy): injection-site soreness, tiredness, headache, muscle aches, or nausea

Timing and duration: These reactions are usually mild and typically settle within a day or two.

Home care (baby): Keep your baby comfortable and well-fed. A mild fever or fussiness usually passes quickly. Acetaminophen or ibuprofen can be used for babies if needed and age-appropriate — check with a provider or pharmacist on dosing. Do not give ASA (Aspirin) to children.

When to call a provider: If your baby seems unusually unwell, has a high or persistent fever, or you're worried, it's always reasonable to call.

Many babies have little or no reaction, and that does not mean the protection didn't work.

Rare but important

  • Severe allergic reaction (anaphylaxis) — reported rarely after any injection; exact frequency varies by source.
  • RSV products are relatively new, so they continue to be monitored closely. No common serious effects have been identified in the studies and use to date.

What providers do to reduce risk: Providers ask about allergy history before giving the injection and are equipped to recognize and treat a severe allergic reaction.

Observation period: Staying nearby for a short time after the injection is recommended, as severe allergic reactions — though rare — typically occur shortly after.

A note on monitoring: Because RSV protection for infants is newer than many vaccines, it's under active safety surveillance — part of the ongoing monitoring described on the Safety & Ingredients page.

Get urgent help now if your baby has:

  • Trouble breathing, fast breathing, or visible effort to breathe (e.g. the skin pulling in around the ribs)
  • Pauses in breathing, or turning blue/grey around the lips
  • Swelling of the lips, tongue, throat, or face after the injection
  • Widespread hives together with breathing difficulty
  • Severe weakness, limpness, or being very difficult to wake
  • Not feeding, or far fewer wet diapers (signs of dehydration)
  • A high or persistent fever, especially in a very young baby
  • Any symptom that feels serious or is rapidly getting worse

If any of these occur, go to the nearest emergency department or call 911. Some of these are signs of RSV illness itself (which protection reduces but can't always prevent), and some relate to a rare reaction to the injection — either way, they need prompt attention.

Who should pause or speak with a healthcare provider first

Speak with a healthcare provider before this protection if:

  • Your baby has had a serious allergic reaction to a previous dose of an RSV product or any component
  • Your baby has a bleeding/clotting disorder (relevant for any injection) — a provider can advise on precautions
  • Your baby is moderately or severely unwell right now (it may be reasonable to wait)
  • For Abrysvo in pregnancy: discuss timing with your pregnancy provider, as it's given in a specific window (32–36 weeks) for babies due during RSV season

These usually do NOT prevent RSV protection:

  • A mild cold or other minor illness without fever
  • Currently breastfeeding (Beyfortus is given to the baby regardless; breastfeeding is encouraged)
  • Prematurity — in fact, premature babies are a priority group for protection
  • A stable, ongoing health condition (often a reason protection is more strongly recommended)
  • Receiving routine vaccines around the same time

Questions parents often ask

Not exactly. Beyfortus (nirsevimab) is a monoclonal antibody — it gives the baby ready-made protective antibodies directly, rather than training the baby's own immune system to make them (which is what a vaccine does). The upside is immediate protection; the trade-off is that it fades over several months, which is fine because it covers the baby's most vulnerable first RSV season.
Usually no — one is enough. If you received Abrysvo during pregnancy, your baby is generally already protected and doesn't also need Beyfortus. Both are used together only in specific situations (for example, a high-risk infant, or a baby born within about two weeks of the maternal vaccine when protection may not have fully transferred). A provider will advise.
Both protect babies well. NACI and Ontario's program prefer the infant antibody (Beyfortus) based on its effectiveness and duration. The maternal vaccine (Abrysvo) is a good alternative — for example, if you'd rather your baby not receive an injection, or it fits your circumstances better. Your pregnancy or child's provider can help you choose.
No. Neither product contains live virus. Beyfortus is just antibodies; Abrysvo contains a purified protein, not the whole virus. They can't cause RSV. They reduce the chance of severe RSV illness, though no protection is perfect, so a milder cold-like illness is still possible.
Typically between 32 and 36 weeks of pregnancy, when the baby is due during RSV season. This timing gives the parent's body time to make antibodies and pass them to the baby before birth. Ask your pregnancy provider (doctor, midwife, or obstetrician) about eligibility and timing.
Not necessarily. RSV protection is designed to reduce severe illness and hospitalization, not to prevent every cough or cold. A milder illness can still happen, and many colds are caused by other viruses entirely. If your baby has trouble breathing or feeding, seek care regardless (see the urgent list above).
Beyfortus (for the baby) may be given at the hospital after birth, or through your baby's healthcare provider or public health unit during RSV season. Abrysvo (in pregnancy) may be available through primary care, obstetricians, midwives, hospitals, or some public health units. Ask your pregnancy or child's provider. See the Resources page for links.
Eligibility (birth-date ranges, age cut-offs, high-risk criteria) is set each season and can change year to year. The most reliable way is to ask your pregnancy provider or your baby's healthcare provider, or check Ontario's RSV prevention program page and your local public health unit. See the Resources page for links.
Mild soreness, redness, fussiness, or a low fever for a day or two are common and expected. Review the "Get urgent help now" list above — if any of those signs occur, seek urgent care. Otherwise, contact a healthcare provider with any concerns.

What we know about RSV protection

Fact Both the infant antibody (Beyfortus) and the maternal vaccine (Abrysvo) have been shown in studies to substantially reduce severe RSV illness and hospitalization in babies.
Concern Because RSV protection for infants is new, some parents wonder whether it's been studied enough, or feel hesitant about something they didn't have for older siblings.
Evidence "New to the program" isn't the same as "untested." Both products went through clinical trials and Health Canada review before authorization, and they're now under active safety monitoring as they're used more widely. The reason they feel new is that, until recently, there simply wasn't a good way to protect babies from RSV — these are a genuine advance, not a rushed product.
Takeaway RSV protection is newly available but well studied, and it addresses a real gap — severe RSV in young babies was previously very hard to prevent.
Fact RSV is one of the most common reasons young babies are hospitalized — even healthy, full-term babies.
Concern Some parents feel that since "everyone gets RSV" and most kids are fine, protection isn't really necessary.
Evidence It's true that nearly all children catch RSV and most recover at home. But in the youngest babies, RSV can cause bronchiolitis or pneumonia serious enough to need hospital care — and it isn't always possible to predict which baby will become very ill. Protection focuses on reducing those severe outcomes during the first, most vulnerable season.
Takeaway The aim isn't to prevent every RSV cold, but to lower the risk of the serious illness that lands young babies in hospital — a meaningful benefit even though most children ultimately recover.

What to do next

If you're pregnant

Ask your pregnancy provider (doctor, midwife, or obstetrician) about RSV protection — whether the maternal vaccine (Abrysvo) at 32–36 weeks or planning Beyfortus for your baby suits you best.

If your baby is born / newborn

Beyfortus may be offered at the hospital after birth, or through your baby's provider during RSV season. Ask whether your baby is eligible.

Check eligibility for the season

Eligibility is set each season. Confirm current criteria with your provider, your public health unit, or Ontario's RSV program page.

Usually one option, not both

If you had Abrysvo in pregnancy, your baby usually doesn't also need Beyfortus. A provider confirms what's right for you.

High-risk children

Premature babies and those with certain conditions may be eligible up to 24 months and have specific recommendations — ask your provider.

Keep a record

Note whether your baby got Beyfortus, or you got Abrysvo in pregnancy, on the health record. See the Resources page.

Where this information comes from

This page is based on:

Last reviewed: June 2026  ·  Next review due: December 2026
Schedules, products, and eligibility can change. Always confirm current details with your healthcare provider, your local public health unit, or official Ontario sources.

Please note: This is an independent website. It is not affiliated with, endorsed by, or operated by the Government of Ontario, the Ministry of Health, or any public health unit. The information here is for general education only and is not medical advice — always consult a licensed healthcare provider about your or your child's immunizations.